Phase 2 Trial Finds Daily Vitamin C May Extend Survival in Pre-Leukemia Patients

Key points

• The EVITA trial enrolled 109 patients with clonal cytopenia of undetermined significance (CCUS) or myelodysplastic syndrome (MDS), conditions that can progress to acute myeloid leukemia.
• Participants in the treatment group received 1,000 mg of oral vitamin C daily for 12 months, while the control group received a placebo.
• More than half of the participants had insufficient vitamin C levels at the start of the study, which were corrected to normal levels in the supplementation group.
• An exploratory analysis showed that patients taking vitamin C were significantly more likely to be alive after approximately three years compared to those taking a placebo.
• The supplement altered cytokine levels associated with favorable outcomes but did not significantly reduce the rate of abnormal blood cell expansion.
• Researchers emphasize that these preliminary results require verification in a larger phase 3 trial before clinical recommendations can be made.

Background

This development follows a 2016 pilot study by the same research team, which confirmed that oral vitamin C could effectively raise blood concentrations. It aligns with a broader scientific shift toward 'cancer interception,' where interventions target biological changes before cancer becomes established. This contrasts with earlier decades of research, where inconsistent findings regarding vitamin C and cancer led to skepticism, particularly after trials using oral supplements showed no benefit for solid tumors.

How outlets are covering it

ScienceDaily highlights the potential for a simple, accessible intervention to improve care for patients currently limited to 'watch and wait' monitoring. The outlet emphasizes the biological mechanism involving the TET2 enzyme and epigenetic regulation. CancerNetwork frames the findings as a potential 'epigenetic interception strategy,' focusing on the theoretical basis for using vitamin C to restore normal gene regulation in pre-leukemic cells. Both sources agree that the results are promising but preliminary, with CancerNetwork noting the need for further validation to confirm the survival benefits observed in the phase 2 trial.

Why it matters

For patients with CCUS or MDS, who often lack approved treatments to prevent progression to leukemia, this study offers a potential new avenue for early intervention. If confirmed in larger trials, daily vitamin C could provide a low-cost, accessible method to improve survival and reduce adverse events in a population currently facing limited therapeutic options.

What to watch

Researchers are continuing to analyze EVITA data to understand the biological mechanisms behind the survival benefit. The primary next step is the launch of a larger phase 3 clinical trial to verify the findings and determine if vitamin C supplementation can reliably improve outcomes for patients with precancerous blood disorders.